货号：M1455

储存条件：粉末-20°C可保存3年；液体-80°C可保存12月。 

产品描述

Cysteinyl leukotrienes (CysLTs, including LTC4, LTD4, and LTE4), mainly produced by eosinophils, mast cells, and macrophages in response to a variety of stimuli activating arachidonate 5-lipoxygenase pathway, are important inflammatory mediators. CysLT1 receptor (LTR1) expresses in human lung smooth muscle cells, lung macrophages, most peripheral blood eosinophils and pregranulocytic CD34+ cells, and in subsets of monocytes and B lymphocytes. Montelukast Sodium is a potent, selective and competitive LTR1 antagonist with IC₅₀ value < 5 nM and are currently used in the treatment of asthma. Nonsmoking patients with asthma treated with Montelukast Sodium(200mg, three times daily for 10 1/3 days) showed improvements in FEV₁, compared with placebo-treated patients. In C57BL/6 mice with asthma induced by chronic exposure to ovalbumin, Montelukast (6 mg/kg, once daily for 20 days) treatment significantly suppressed the increased eosinophils in bronchoalveolar lavage (BAL) fluid and lung tissue, and increased IL-5 level in BAL fluid in models. It was also proved that Montelukast inhibited the diabetes-induced capillary and neuronal degeneration in streptozotocin-induced diabetes mouse model. 

作用机制

Montelukast Sodium is a potent competing ligand for high affinity [³H]LTD4 specific binding. 

产品信息